Apeloa Pharmaceutical's cefditoren pivoxil API receives marketing approval

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Apeloa Pharmaceutical Co., Ltd. announced that its wholly owned subsidiary Zhejiang Apeloa Debang Pharmaceutical Co., Ltd. has received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice for cefditoren pivoxil issued by the National Medical Products Administration, with registration number Y20250000349 and packaging specifications of 5 kg per drum, 10 kg per drum, and 25 kg per drum. Cefditoren pivoxil is a third-generation cephalosporin antibiotic indicated for infections of the respiratory tract, urinary system, biliary tract, skin and soft tissue, as well as infections in obstetrics and gynecology, ophthalmology, and stomatology caused by susceptible bacteria. The company stated that this approval signifies that the API is qualified for domestic sales, which will broaden the company's product pipeline and advance the development of its API business, while also noting that pharmaceutical production and sales are subject to uncertainties arising from policies, regulations, and the market environment.

Impact on assets 1

Others▲ · 1 stocks
Apeloa Pharmaceutical Co Ltd
000739
▲ PositiveRegulationrelevance

Wholly owned subsidiary Zhejiang Apeloa Debang received NMPA marketing approval for cefditoren pivoxil API, qualifying it for domestic sales and broadening the product pipeline.

Off-coverage companies 1

浙江普洛得邦制药有限公司Private▲ Positive
Regulationrelevance

The subsidiary itself received the NMPA Chemical API Marketing Application Approval Notice for cefditoren pivoxil, allowing domestic sales.

© 2026 MarketIVNews